Barely Significant
← all excerpts

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.

Front Cardiovasc Med · 2023 · PMC10315496 · PMID 37404744

Europe PMCDOI
1
hedged sentence
0.0930
closest p · 1.9× alpha
0.0930
boldest claim

The sentences

a trend toward significancep = 0.093so close (0.05 < p ≤ 0.1)
This was also confirmed in the multivariable analysis, each LDL-C increase by 10 mg/dl was associated with 10% increase of the chance of administration of alirocumab at the dose of 150 mg/dl Q2W for the whole cohort (OR = 1.10; 95% CI: 1.07–0.1.13), with significant results for the other countries group, and with only a trend toward significance in the CEE group (OR = 1.06; 95%CI: 0.99–1.14; p = 0.093) ( Table 3 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.